Patents Represented by Attorney, Agent or Law Firm Sean A. Johnston
  • Purified forms of DNase
    Patent number: 6440412
    Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: August 27, 2002
    Assignee: Genentech, Inc.
    Inventors: John Frenz, Steven J. Shire, Mary B. Sliwkowski
  • Human DNase I hyperactive variants
    Patent number: 6391607
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: May 21, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • Human DNase II
    Patent number: 6265195
    Abstract: This invention relates to a novel human deoxyribonuclease, referred to as human DNase II. The invention provides nucleic acid sequences encoding human DNase II, thereby enabling the production of human DNase II by recombinant DNA methods in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and diagnostic and therapeutic uses of human DNase II.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: July 24, 2001
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Will F. Baron
  • Method for culturing recombinant cells
    Patent number: 6235498
    Abstract: A method for culturing a recombinant host cell comprising: determining a polypeptide factor for a polypeptide factor-dependent host cell; transforming said host cell with nucleic acid encoding said polypeptide factor; transforming the host cell with nucleic acid encoding a desired protein; and, culturing the transformed host cells in a medium lacking the polypeptide factor.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: May 22, 2001
    Assignee: Genentech, Inc.
    Inventors: Jennie P. Mather, Axel Ullrich
  • Method for culturing recombinant cells
    Patent number: 6232117
    Abstract: A method for culturing a recombinant host cell comprising: determining a polypeptide factor for a polypeptide factor-dependent host cell; transforming said host cell with nucleic acid encoding said polypeptide factor; transforming the host cell with nucleic acid encoding a desired protein; and, culturing the transformed host cells in a medium lacking the polypeptide factor.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: May 15, 2001
    Assignee: Genentech, Inc.
    Inventor: Jennie P. Mather
  • Ocular gene therapy
    Patent number: 6204251
    Abstract: The invention relates to methods of ocular gene therapy.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: March 20, 2001
    Assignee: Genentech, Inc.
    Inventor: R. Andrew Cuthbertson
  • Human trk receptors and neurotrophic factor inhibitors
    Patent number: 6027927
    Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobin sequences.
    Type: Grant
    Filed: October 1, 1997
    Date of Patent: February 22, 2000
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
  • Antibodies to leukemia inhibitory factor
    Patent number: 5980894
    Abstract: The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.
    Type: Grant
    Filed: April 10, 1997
    Date of Patent: November 9, 1999
    Assignee: Genentech, Inc.
    Inventor: Kyung Jin Kim
  • Pantropic neurotrophic factors
    Patent number: 5981480
    Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: November 9, 1999
    Assignee: Genentech, Inc.
    Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow
  • CHO cell sialidase by recombinant DNA technology
    Patent number: 5928915
    Abstract: A recombinant cell line has a constitutive sialidase whose functional expression is disrupted, for example by homologous recombination or using antisense RNA. Sialidase is purified from cell culture fluid of Chinese hamster ovary cells. DNA encoding sialidase is obtained using an oligonucleotide probe designed using amino acid sequence data on the sialidase, and the DNA is expressed in host cells transformed with the DNA.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: July 27, 1999
    Assignee: Genentech, Inc.
    Inventors: Thomas G. Warner, Mary B. Sliwkowski
  • Human TRK receptors and neurotrophic factor inhibitors
    Patent number: 5844092
    Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: December 1, 1998
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
  • Neurotrophic factor
    Patent number: 5830858
    Abstract: A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4.beta. and NT-4.gamma.. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: November 3, 1998
    Assignee: Genentech, Inc.
    Inventor: Arnon Rosenthal
  • AL-1 neurotrophic factor antibodies
    Patent number: 5798448
    Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: August 25, 1998
    Assignee: Genentech, Inc.
    Inventors: Ingrid W. Caras, John W. Winslow
  • Purified forms of DNase
    Patent number: 5783433
    Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 21, 1998
    Assignee: Genentech, Inc.
    Inventors: John Frenz, Mary B. Sliwkowski
  • Monoclonal antibodies to human leukemia inhibitory factor
    Patent number: 5688681
    Abstract: The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: November 18, 1997
    Assignee: Genentech, Inc.
    Inventor: Kyung Jin Kim
  • DNA for expression of bovine growth hormone
    Patent number: 5489529
    Abstract: High-level expression of bovine growth hormone is achieved using DNA encoding bovine growth hormone which, when transcribed, produces messenger RNA (mRNA) that at its 5' end is substantially free of secondary structure that is capable of interfering with translation of the mRNA.
    Type: Grant
    Filed: July 19, 1993
    Date of Patent: February 6, 1996
    Inventors: Herman A. de Boer, Herbert L. Heyneker, Peter H. Seeburg
  • Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
    Patent number: 5364769
    Abstract: A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. NT-4 is used in the treatment of nerve cells and in diagnostic assays.
    Type: Grant
    Filed: September 25, 1990
    Date of Patent: November 15, 1994
    Assignee: Genentech, Inc.
    Inventor: Arnon Rosenthal
  • Production of vascular endothelial cell growth factor and DNA encoding same
    Patent number: 5332671
    Abstract: DNA isolates coding for a vascular endothelial cell growth factor may be used to produce the protein via recombinant expression systems. Such protein is useful therapeutically to treat conditions in which a selective action on the vascular endothelial cells, in the absence of excessive connective tissue proliferation, is desirable.
    Type: Grant
    Filed: August 4, 1989
    Date of Patent: July 26, 1994
    Assignee: Genetech, Inc.
    Inventors: Napoleone Ferrara, David W.-H. Leung
  • Human nerve growth factor by recombinant technology
    Patent number: 5288622
    Abstract: The .beta.-subunit of human nerve growth factor (.beta.NGF) is prepared in essentially pure form in commercially viable quantities using recombinant DNA technology. The nucleotide sequence and vectors encoding human .beta.NGF and host cells transformed with the vectors are also provided.
    Type: Grant
    Filed: June 11, 1992
    Date of Patent: February 22, 1994
    Assignee: Genentech, Inc.
    Inventors: Alane M. Gray, Axel Ullrich
  • Purified forms of DNASE
    Patent number: 5279823
    Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.
    Type: Grant
    Filed: June 8, 1992
    Date of Patent: January 18, 1994
    Assignee: Genentech, Inc.
    Inventors: John Frenz, Steven J. Shire, Mary B. Sliwkowski